News Releases

December 20, 2018

Indivior Publishes Design and Patient Characteristics for Real-World Study of Life Changes in People Treated with SUBLOCADE™ (Buprenorphine Extended-Release) in Contemporary Clinical Trials

December 18, 2018

Trading Update Release

December 12, 2018

Court of Appeals for the Federal Circuit Declines to Immediately Issue Mandate After Preliminary Injunction Ruling

November 30, 2018

Indivior Prepays Debt

November 23, 2018

Indivior Announces Health Canada Approval of SUBLOCADE™ (Buprenorphine Extended-Release) Injection for Patients with Moderate to Severe Opioid Use Disorder

November 21, 2018

Court of Appeals for the Federal Circuit Lifts Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film

November 20, 2018

Indivior Statement on Court Decision

November 19, 2018

PERSERIS™, the First Once-Monthly Risperidone-Containing Subcutaneous Long-Acting Injectable, Now Available in the U.S. for the Treatment of Schizophrenia in Adults

November 6, 2018

Indivior Announces Upcoming Investor Events

November 1, 2018

Indivior Q3 2018 Financial Results